» Articles » PMID: 29163543

Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells

Overview
Journal Front Immunol
Date 2017 Nov 23
PMID 29163543
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Epithelial ovarian cancer (EOC) remains a highly lethal gynecological malignancy. Ascites, an accumulation of peritoneal fluid present in one-third of patients at presentation, is linked to poor prognosis. High levels of regulatory T cells (Tregs) in ascites are correlated with tumor progression and reduced survival. Malignant ascites harbors high levels of Tregs expressing the tumor necrosis factor receptor 2 (TNFR2), as well as pro-inflammatory factors such as interleukin 6 (IL-6) and tumor necrosis factor (TNF). IL-6 is also associated with poor prognosis. Herein, we study the effect of IL-6 and TNF present in ascites on the modulation of TNFR2 expression on T cells, and specifically Tregs.

Methods: Ascites and respective peripheral blood sera were collected from 18 patients with advanced EOC and soluble biomarkers, including IL-6, sTNFR2, IL-10, TGF-β, and TNF, were quantified using multiplexed bead-based immunoassay. Peripheral blood mononuclear cells (PBMC) from healthy donors were incubated with cell-free ascites for 48 h (or media as a negative control). In some experiments, IL-6 or TNF within the ascites were neutralized by using monoclonal antibodies. The phenotype of TNFR2 Tregs and TNFR2 Tregs were characterized post incubation in ascites. In some experiments, cell sorted Tregs were utilized instead of PBMC.

Results: High levels of immunosuppressive (sTNFR2, IL-10, and TGF-β) and pro-inflammatory cytokines (IL-6 and TNF) were present in malignant ascites. TNFR2 expression on all T cell subsets was higher in post culture in ascites and highest on CD4CD25FoxP3 Tregs, resulting in an increased TNFR2 Treg/effector T cell ratio. Furthermore, TNFR2 Tregs conditioned in ascites expressed higher levels of the functional immunosuppressive molecules programmed cell death ligand-1, CTLA-4, and GARP. Functionally, TNFR2 Treg frequency was inversely correlated with interferon-gamma (IFN-γ) production by effector T cells, and was uniquely able to suppress TNFR2 T effectors. Blockade of IL-6, but not TNF, within ascites decreased TNFR2 Treg frequency. Results indicating malignant ascites promotes TNFR2 expression, and increased suppressive Treg activity using PBMC were confirmed using purified Treg subsets.

Conclusion: IL-6 present in malignant ovarian cancer ascites promotes increased TNFR2 expression and frequency of highly suppressive Tregs.

Citing Articles

Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?.

Wu Y, Chen D, Gao Y, Xu Q, Zhou Y, Ni Z Hum Cell. 2024; 37(4):931-943.

PMID: 38814516 DOI: 10.1007/s13577-024-01083-w.


Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.

He R, Huang S, Lu J, Su L, Gao X, Chi H Front Immunol. 2024; 15:1362709.

PMID: 38415252 PMC: 10897008. DOI: 10.3389/fimmu.2024.1362709.


Exploration of the effect and mechanism of Scutellaria barbata D. Don in the treatment of ovarian cancer based on network pharmacology and in vitro experimental verification.

Zhang J, Qi C, Li H, Ding C, Wang L, Wu H Medicine (Baltimore). 2023; 102(51):e36656.

PMID: 38134066 PMC: 10735072. DOI: 10.1097/MD.0000000000036656.


Therapeutic potential of TNFR2 agonists: a mechanistic perspective.

Chen Y, Jiang M, Chen X Front Immunol. 2023; 14:1209188.

PMID: 37662935 PMC: 10469862. DOI: 10.3389/fimmu.2023.1209188.


Distribution characteristics and clinical significance of infiltrating T cells in the tumor microenvironment of pancreatic cancer.

Sun G, Yang Z, Fang K, Xiong Y, Tu S, Yi S Oncol Lett. 2023; 25(6):261.

PMID: 37205920 PMC: 10189847. DOI: 10.3892/ol.2023.13847.


References
1.
Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

2.
Zheng Y, Josefowicz S, Kas A, Chu T, Gavin M, Rudensky A . Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007; 445(7130):936-40. DOI: 10.1038/nature05563. View

3.
Chen Y, Mu C, Huang J . Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2013; 98(6):751-5. DOI: 10.1177/030089161209800612. View

4.
Kampan N, Xiang S, McNally O, Stephens A, Quinn M, Plebanski M . Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities. Curr Med Chem. 2017; 25(36):4785-4806. DOI: 10.2174/0929867324666170712160621. View

5.
Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T . Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986; 324(6092):73-6. DOI: 10.1038/324073a0. View